Codexis (CDXS) Q2 FY26 earnings call

Codexis reported solid Q2 FY26 results, driven by a return to growth in its small molecule biocatalysis business and significant advancements in its EcoSynthesis platform. The company successfully raised $25 million in new capital, extending its cash runway through 2028, and is progressing with its GMP manufacturing facility construction. Management is focused on industrializing the EcoSynthesis technology to address the anticipated siRNA manufacturing bottleneck and secure higher-value contracts, while also managing expenses to achieve profitability.